SCHEMBL21471613

SCHEMBL21471613

Cc1nnn(Cc2ccccc2)c1C(=O)c1cc2c(s1)-c1ccc(F)cc1NCC2

nearest known ligand 0.32

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 4/20 0.32
HPGD P15428 3/20 0.32
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PKM P14618 1/20 0.32
LMNA P02545 1/20 0.32
P2RX7 Q99572 1/20 0.32
PIK3CA P42336 1/20 0.32
TP53 P04637 2/20 0.31
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CYP1A2 P05177 1/20 0.31
GRM5 P41594 1/20 0.31
GRM2 Q14416 1/20 0.31
MAPK14 Q16539 1/20 0.31
HTR2C P28335 1/20 0.31
HTR2B P41595 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21471605 0.81 SCD (0.31) HPGDKDM4EALDH1A1TDP1L3MBTL1
SCHEMBL21474611 0.78 LMNA (0.36) HPGDALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL21471796 0.77 MAPK14 (0.47) NOTUMHPGDKDM4EALDH1A1L3MBTL1
SCHEMBL21474623 0.76 MAPT (0.36) KDM4EALDH1A1L3MBTL1LMNAHTT
SCHEMBL20599149 0.72 KDM4E (0.57) NOTUMHPGDKDM4EALDH1A1TDP1
SCHEMBL20619706 0.70 KDM4E (0.56) NOTUMHPGDKDM4EALDH1A1TDP1
SCHEMBL21471711 0.70 DHODH (0.34) NOTUMHPGDKDM4EALDH1A1L3MBTL1
SCHEMBL21471602 0.70 GABRP (0.36) NOTUMHPGDKDM4EALDH1A1L3MBTL1
SCHEMBL21471603 0.68 NOTUM (0.38) NOTUMHPGDKDM4EALDH1A1L3MBTL1
SCHEMBL21471733 0.68 NOTUM (0.33) NOTUMHPGDKDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975094-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-04-13 US disclosed
US-20190315766-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-10-17 US disclosed
WO-2019199908-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975094-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 NOTUM 1555/4885HPGD 167/4885KDM4E 1288/4885
US-20190315766-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 NOTUM 1555/4885HPGD 167/4885KDM4E 1288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.